<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072072</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000335434</org_study_id>
    <secondary_id>UCLA-0306083</secondary_id>
    <nct_id>NCT00072072</nct_id>
  </id_info>
  <brief_title>Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
      Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary&#xD;
      for their growth. Combining celecoxib with erlotinib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when&#xD;
      given together with erlotinib in treating patients with stage IIIB or stage IV non-small cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the biologically active dose of celecoxib administered with erlotinib in&#xD;
           patients with stage IIIB or IV non-small cell lung cancer.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the clinical activity of this regimen, in terms of reduction in tumor burden,&#xD;
           in these patients.&#xD;
&#xD;
        -  Correlate biological endpoints with cyclooxygenase-2 and epidermal growth factor&#xD;
           receptor inhibition in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, dose-escalation study of celecoxib.&#xD;
&#xD;
      Patients receive oral erlotinib once daily and oral celecoxib twice daily on days 1-28.&#xD;
      Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients with stable or responding disease may continue treatment&#xD;
      beyond 2 courses at the investigator's discretion.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of celecoxib until the maximum tolerated&#xD;
      dose (MTD) and biologically active dose (BAD) are determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).&#xD;
      The BAD is defined as the maximum decrease in the level of PGE_2 where no DLT occurs.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 21-27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIB or IV&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Progressive disease after at least 2 prior standard chemotherapy regimens OR refused&#xD;
             standard chemotherapy&#xD;
&#xD;
          -  No active CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  21 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  PT and/or PTT no greater than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No symptomatic ventricular arrhythmia&#xD;
&#xD;
          -  No symptomatic conduction abnormality&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior gastrointestinal ulceration, bleeding, or perforation&#xD;
&#xD;
          -  No hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or other&#xD;
             reagents used in this study&#xD;
&#xD;
          -  No concurrent disease or medical condition that would preclude study treatment or&#xD;
             compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior corticosteroids&#xD;
&#xD;
          -  No concurrent steroids (including chronic use)&#xD;
&#xD;
               -  Concurrent topical steroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior non-cytotoxic investigational agents&#xD;
&#xD;
          -  More than 3 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  No prior cyclooxygenase-2 (COX-2) inhibitors for metastatic NSCLC&#xD;
&#xD;
          -  No prior epidermal growth factor receptor inhibitor for metastatic NSCLC&#xD;
&#xD;
          -  No concurrent COX-2 inhibitors&#xD;
&#xD;
          -  No concurrent NSAIDs&#xD;
&#xD;
          -  No concurrent fluconazole or lithium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Figlin, MD, FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Rickard</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8.</citation>
    <PMID>16740761</PMID>
  </results_reference>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

